SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending due to significant momentum and volume, leading to a breakout and potential short squeeze. Community members are actively discussing profit-taking strategies, with some suggesting the stock could become the next low-float runner. The stock's low float and potential for a squeeze are major talking points.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversations around DJT are heavily focused on political affiliations following a shooting involving Charlie Kirk, with community members debating the shooter's motives and ideological alignment. Some users are pointing fingers between the left and right, while others are highlighting the broader implications of political rhetoric and violence. The stock is also being discussed in relation to broader market trends and potential financial impacts.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities is trending as the community anticipates a potential short squeeze following the completion of its merger with Strive Enterprises; traders are closely watching for a CUSIP change and its potential impact on short positions. Chatter revolves around the possibility of the company investing its substantial treasury into Bitcoin, drawing comparisons to other companies in the crypto space. Some traders express frustration that the price has not yet reflected the merger news and the potential for a short squeeze.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP.X is trending as the community speculates on potential catalysts, including a possible spot ETF and upcoming rate cuts, while also closely monitoring price action and key resistance levels. Discussions include both bullish sentiment, with some anticipating a significant breakout, and skepticism regarding its performance compared to other cryptocurrencies. Traders are actively debating strategies around accumulating and holding versus taking profits.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending as traders anticipate Phase 3 data, expected mid-September, with the community actively debating potential outcomes and price targets. Bullish sentiment is fueled by recent institutional buying and analyst ratings, while bears cite concerns over trial design and past performance, with some highlighting the involvement of controversial figures known for short selling. The potential for a short squeeze and the high implied volatility are adding to the speculative buzz.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending after its IPO, with the community actively discussing its potential and comparing it to other recent IPOs. Some investors are excited about the company's prospects and credit card rewards program, while others express concerns about its valuation and potential for a pullback. The stock's initial trading volatility and comparison to other crypto-related companies are also key talking points.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking significant price movement and active discussion about its potential. The community is focused on the stock's low float and speculating about a potential short squeeze, while also keeping an eye on an upcoming investor summit. Some traders are also wary of dilution and high volatility.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to the excitement surrounding its upcoming listing on BiFinance and a live 'Biggest Buy Contest', which the community sees as key catalysts. The community emphasizes that the project is built on organic growth and hard work, not hype, and they are rallying together to push the coin to new all-time highs. Many community members express strong conviction and encourage others to DYOR and join their Telegram group to learn more.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending downwards as reports circulate that the Trump administration may link COVID-19 vaccines to child deaths, creating uncertainty around the stock's future. The community is discussing the potential impact of this news, while some investors see a buying opportunity due to the perceived overreaction and low valuation. Discussions also include Moderna's pipeline beyond COVID-19, especially its personalized cancer vaccine program.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid discussions around the implications of potential shifts in government policy regarding COVID-19 vaccines, including concerns about linking vaccines to child deaths. The community is weighing the potential impact on Pfizer's revenue and future prospects, with some questioning liability and others pointing to the company's broader pipeline beyond vaccines. Additionally, some traders are closely monitoring technical indicators and dividend payouts, viewing the dip as a possible buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates

Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +4.84% and +26.21%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +218.52% and +66.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children

The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17.
read more...

Q4 2023 Vivos Therapeutics Inc Earnings Call Transcript

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript

Vivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call Transcript...

VVOS Stock Earnings: Vivos Therapeutics Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
VVOS stock results show that Vivos Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth...

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call

Call Scheduled for Today, Thursday, March 28, 2024 at 5:00 pm ETLITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ( Vivos or the Company ) (NASDAQ: VVOS), a leading...

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Littleton, CO.

Current Price	$3.47
Prev Close	$3.64
Open	$3.65
Dividend Yield	0.00%
50-Day Moving Average	$4.85
Beta	0.65
Avg. Volume	183,610.19
PE Ratio	-1.94

52-Week High	$7.95
52-Week Low	$1.98
Market Capitalization	$27.32M
EPS (Annual)	-$2.22
Price to Book	5.82
Revenue Per Employee	$137,899.08
Enterprise Value/EBITDA	N/A

VVOS
Vivos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VVOS News

VVOS Vivos Therapeutics Inc